Bristol Myers’ cell therapy chief Lynelle Hoch explains the reagent behind its autoimmune CAR-T pause and a puzzling MS trial ...
Al Sandrock is calling it quits as CEO of Voyager Therapeutics in the first quarter next year, but he will stay on the board.
Gilead pays $1.28B upfront to China's PepStar Therapeutics for oral IL-23 inhibitor HCXT-2001, targeting IBD and psoriasis, ...
The Swiss pharma is teaming up with Zymeworks, paying $55 million upfront for worldwide rights to a trispecific T cell ...
Biopharma M&A, licensing upfronts and VC all cooled in Q3, DealForma data show, while China’s share of pharma in-licensing kept climbing.
A key Republican congressman asked the Trump administration to restrict the stream of money into China’s biotech sector, threatening to squelch the dealmaking that’s become big ...
Alnylam & Regeneron's siRNA therapy brezosiran reduced mutant huntingtin protein 60-64% in 9 patients, spurring plans for a ...
Treasury’s draft outbound investment rules would sharply limit US deals for Chinese drug and biotech assets, opening a 45-day ...
AbbVie’s IL-1α and IL-1β inhibitor lutikizumab improved patient response rates after 16 weeks by a statistically significant ...
Sanofi breaks ground on a Frankfurt insulin plant, FDA warns Baxter over cephalosporin contamination, and radiopharma players ...
Roche touts 88% Phase 3 success rate as it culls afimkibart’s AD trial and seven early assets ahead of giredestrant launch.
Arbutus' AB-101 hold lifted; GSK drops HBV drug; Ultomiris approved for IgAN; Biohaven resubmits SCA app; Arcus raises $250M; ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results